MedTrace Logo

PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy

NCT00390598 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2011-03-24

No results posted yet for this study

Summary

The trial compares Laxabon® 4L versus Pursennid® Ex-Lax 36mg and 2L Laxabon® for large bowel cleansing prior to colonoscopy allocating patients planned for colonoscopy to one of the two cleansing regimens.

Conditions

  • Colonoscopy

Interventions

DRUG

PEG (solution given 4 L)

DRUG

senna glycoside 36 mg and PEG (solution given 2 L)

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Peter Naredi, MD, PhD · Umeå University

  • Markku M Haapamaki, MD, PhD · Umeå University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390598 on ClinicalTrials.gov